DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02150707

Completed

The Differential Effects of Diabetes Therapy on Inflammation

Assets

Exenatide / Liraglutide

Listed sites

1

Recruiting sites

—

Enrollment

17

actual

Study population

Chronic kidney disease, Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02150707
Org study IDDPP4201401

Timeline

Milestones

Study first posted2014-05-30estimated
Last update posted2016-05-18estimated
Study start2014-05 (month precision)
Primary completion2015-12actual (month precision)
Study completion2015-12actual (month precision)

Assets

Investigational agents

ExenatideLiraglutide

Study populations

Who this study enrolls

Chronic kidney diseaseType 2 diabetes

Eligibility

Who can enroll

Minimum age30 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

This study will be a prospective cohort study with 120 participants: 40 per group. I have calculated this sample size to achieve a 90% power based on a 50% reduction in urinary chemokines and circulating pro-inflammatory immune cells 1-4. This power calculation anticipates a 10% dropout rate. Patients with DKD presenting to the diabetes service of St Vincent's University Hospital (SVUH) and Mater Misericordiae University Hospital (MMUH) who are commenced on GLP-1, DPP4i or insulin for the first time will be invited to participate in the study.

Inclusion criteria

•Age over 30 years
•Diagnosis of type 2 diabetes for one year or more
•Diagnosis of DKD as defined by two distinct albumin:creatinine ratio measurements above the gender specific range in the local reference laboratory with an interval of no less than eight week between measurements
•Stable dose of an inhibitor of the renin angiotensin system for a period of 8 weeks

Exclusion criteria

•Any cognitive impediment that preclude the participant from giving free and informed consent
•Substance abuse including alcohol excess
•Use of a GLP-1 analogue in the last 6 months
•Pregnancy
•Hypersensitivity to the prescribed treatment

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Renal / kidney

2 endpoints
Primary/protocol endpoint

Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio

Time frame:6 months

ratio, improvement

Secondary/protocol endpoint

Albumin:creatinine ratio

Time frame:6 months

uACR, change

ratio, improvement

LOINC 9318-7

Publications (4)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.